We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
Cap. Flow
+$254M
Cap. Flow %
266.32%
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99

Top Buys

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.6M
2
BAX icon
Baxter International
BAX
+$3.81M
3
AKBA icon
Akebia Therapeutics
AKBA
+$2.87M
4
OTIC
Otonomy, Inc.
OTIC
+$2.46M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$1.81M

Top Sells

1
GILD icon
Gilead Sciences
GILD
+$8.82M
2
CELG
Celgene Corp
CELG
+$6.57M
3
DYAX
DYAX CORPORATION
DYAX
+$6.35M
4
CMG icon
Chipotle Mexican Grill
CMG
+$5.44M
5
VTRS icon
Viatris
VTRS
+$2.57M

Sector Composition

1 Healthcare 48.43%
2 Technology 4.06%
3 Consumer Discretionary 2.5%
4 Consumer Staples 1.74%
5 Materials 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TAP icon
276
PUT
Molson Coors Class B
TAP
$7.84B
$4K ﹤0.01%
2,500
– –
PTLA
277
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4K ﹤0.01%
+21,700
New +$688K
ACAD icon
278
Acadia Pharmaceuticals
ACAD
$4.39B
$3K ﹤0.01%
+108
New +$2.35K
APH icon
279
PUT
Amphenol
APH
$188B
$2K ﹤0.01%
+40,000
New +$519K
XLNX
280
CALL
DELISTED
Xilinx Inc
XLNX
$2K ﹤0.01%
+15,000
New +$704K
LLTC
281
PUT
DELISTED
Linear Technology Corp
LLTC
$2K ﹤0.01%
+1,800
New +$76.1K
HOT
282
PUT
DELISTED
STARWOOD HOTELS & RESORTS WORLDWIDE, INC.
HOT
$2K ﹤0.01%
15,000
+2,500
+20% +$171K
ABT icon
283
CALL
Abbott
ABT
$172B
$1K ﹤0.01%
8,000
– –
IBM icon
284
PUT
IBM
IBM
$206B
$1K ﹤0.01%
7,845
-23,535
-75% -$3.01M
RCKT icon
285
CALL
Rocket Pharmaceuticals
RCKT
$372M
$1K ﹤0.01%
2,500
– –
TNXP icon
286
CALL
Tonix Pharmaceuticals
TNXP
$189M
– –
0
– –
BIG
287
PUT
DELISTED
Big Lots, Inc.
BIG
$1K ﹤0.01%
+8,800
New +$353K
PTLA
288
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1K ﹤0.01%
+59,600
New +$1.89M
SGYP
289
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1K ﹤0.01%
+30,400
New +$110K
CEMP
290
PUT
DELISTED
Cempra, Inc.
CEMP
$1K ﹤0.01%
+1,000
New +$18.1K
ALKS icon
291
PUT
Alkermes
ALKS
$8.66B
– –
-52,400
Closed -$372K
AMGN icon
292
Amgen
AMGN
$201B
– –
-9,400
Closed -$1.4M
BCRX icon
293
CALL
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-9,100
Closed -$3K
BCRX icon
294
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-39,600
Closed -$409K
BCRX icon
295
PUT
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-45,000
Closed -$165K
BLUE
296
DELISTED
bluebird bio
BLUE
– –
-774
Closed -$475K
BUD icon
297
CALL
AB InBev
BUD
$157B
– –
-16,000
Closed -$6K
BUD icon
298
AB InBev
BUD
$157B
– –
-3,700
Closed -$463K
CCEP icon
299
CALL
Coca-Cola Europacific Partners
CCEP
$46.9B
– –
-11,400
Closed -$43K
CCEP icon
300
Coca-Cola Europacific Partners
CCEP
$46.9B
– –
-24,600
Closed -$1.21M
10 11
12
13 14

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q1 2016 Portfolio in Review

As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.

  • FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
  • FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
  • FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
  • FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
  • FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
  • FT Options opened 183 new positions and closed 99 in Q1 2016.
  • FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.

Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.